Biomarkers in drug discovery and development: from target identification through drug marketing.
about
Modelling and simulation as research tools in paediatric drug developmentImplementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical ResearchFunctional biomarkers for the acute effects of alcohol on the central nervous system in healthy volunteers.The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug developmentThe opportunities and challenges of developing imaging biomarkers to study lung function and disease.Nitrite and nitrate levels of gingival crevicular fluid and saliva in subjects with gingivitis and chronic periodontitis.Estimation of salivary and serum total sialic Acid levels in periodontal health and diseaseA novel PET marker for in vivo quantification of myelination.The application of clinical proteomics to cancer and other diseases.How industry is approaching the search for new diagnostic markers and biomarkers.When close is not close enough: a comparison of endogenous and recombinant biomarker stability samples.Development and use of biomarkers in oncology drug development.Kinase selectivity profiling by inhibitor affinity chromatography.Diagnostic biomarkers for oral and periodontal diseases.Microvesicles/exosomes as potential novel biomarkers of metabolic diseasesCellular imaging in drug discovery.Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.Targeted antitumour therapy--future perspectives.Gene expression profiling and its practice in drug development.Biomarkers for the effects of cannabis and THC in healthy volunteers.Validation of analytic methods for biomarkers used in drug developmentSearching for 'omic' biomarkersIndustrialized MS-based proteomics in the search for circulating biomarkers.Systematic analytical validation of commercial kits for the determination of novel biomarkers for clinical drug development.Case studies from the use of commercial biomarker/protein test kits.The role of pharmacokinetic and pharmacokinetic/pharmacodynamic modeling in drug discovery and development.In vitro biomarker discovery for atherosclerosis by proteomics.AutoGenomics, Inc.The demonstration of immunohistochemical biomarkers in methyl methacrylate-embedded plucked human hair follicles.Current practices and future outlook on the integration of biomarkers in the drug development process.Two-dimensional electrophoretic analysis of nuclear matrix proteins in human colon adenocarcinoma.Molecular biomarkers in clinical development: what could we learn from the clinical trial registry?Live-single-cell phenotypic cancer biomarkers-future role in precision oncology?
P2860
Q27010366-F681AB22-01B7-4902-8C6C-D860AD2F03E2Q27024682-E8A84EC7-1C82-432D-A641-09DDAF22EA6DQ30469906-FAA0168C-B572-4907-9603-CA87F0013CEDQ30977143-38A3DD0D-43CF-4044-876B-03CA4D9E4412Q33283655-22CDB5AE-9558-4123-9435-52A43125EA0EQ33972335-03D85C69-11CA-4446-8B92-7D9FC94181BBQ34480017-7742CDD1-2A17-4A76-B5F9-706A7416E5F0Q34603248-01B0C57B-E310-4A0B-B97F-19015940236FQ35621912-1DE7ED51-9691-4E72-B77B-887E2D726176Q35641788-427C774E-8B57-4FD9-9786-AB3016D1A5C9Q35674203-D49C4EDF-60A1-4DF7-92D2-7B6218419109Q35812532-4A95420E-5C9E-4EB0-AC2E-EEB26F1564F6Q36168379-3FBA2072-45C0-4FAE-B743-A2F27FD4B813Q36174692-907047ED-F86F-42F9-B917-1943402ABA4EQ36175435-C0EC44B3-F775-43D2-B236-D2A77174AE4DQ36438745-942FFFDE-D3B3-407A-A418-6305C9872E49Q36611534-37D00D11-9AF7-4EFE-AC13-464AAA01E3D3Q36616922-F02398F4-EA2A-4A7E-B4DB-776DC065B881Q36726630-A8F21B7C-EE71-41FC-9D47-1065F901080CQ37156258-5BA9731A-681E-4714-8592-C336A4559664Q37284255-6CF30E24-7675-4494-BA15-497988A47A21Q37517240-23178DBD-2B3A-43F6-9BCF-DF441F76FEB6Q37810154-08456535-B773-4CC2-9765-E59A79E91F26Q37810247-08B55E9B-D0FD-4EA3-A095-1F30BCAB19EDQ37923936-37226493-10ED-43FD-8C57-9ECF7B349740Q39769308-3B13F1B7-B5BE-4F7B-8641-AA3BA8B4CC29Q40501649-1BECC84A-D961-4B32-BE3B-85F45CA351E8Q46761735-CF464100-C872-4CE1-A8D4-D545C6D9A072Q46837500-A23091EA-3064-4710-802F-F41C40326BC4Q47626694-F5100B97-BCB8-4315-8464-64A7CA612741Q51775649-9AC4292D-6A67-4AB7-8D8D-27E53F28E33DQ54202521-DF57C66C-1947-408B-8E52-CFEA66422B29Q55397731-9066D9AE-CC8C-401F-9ADA-ECCF16CF9124
P2860
Biomarkers in drug discovery and development: from target identification through drug marketing.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Biomarkers in drug discovery a ...... cation through drug marketing.
@ast
Biomarkers in drug discovery a ...... cation through drug marketing.
@en
type
label
Biomarkers in drug discovery a ...... cation through drug marketing.
@ast
Biomarkers in drug discovery a ...... cation through drug marketing.
@en
prefLabel
Biomarkers in drug discovery a ...... cation through drug marketing.
@ast
Biomarkers in drug discovery a ...... cation through drug marketing.
@en
P2860
P356
P1476
Biomarkers in drug discovery a ...... cation through drug marketing.
@en
P2093
Wayne A Colburn
P2860
P304
P356
10.1177/0091270003252480
P577
2003-04-01T00:00:00Z